Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice

Virology Journal

Volumn 11, Issue 1, 2014, Pages

  Chowdhury, Mohammed Ye ^a,b   Seo, Soo Kyung ^a   Moon, Ho Jin ^a,c   Talactac, Melbourne R ^a   Kim, Jae Hoon ^a   Park, Min Eun ^a   Son, Hwa Young ^a   Lee, Jong Soo ^a   Kim, Chul Joong ^a  

^a Chungnam National University   (South Korea)

^b Chittagong Government Veterinary College   (Bangladesh)

^c IOWA STATE UNIVERSITY   (United States)

Author keywords

Broad protection; Humoral immunization; Influenza vaccine; Matrix protein 2

Indexed keywords

ANIMALS; ANTIBODIES, VIRAL; BODY WEIGHT; CROSS PROTECTION; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; GENE EXPRESSION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; LEUKOCYTES, MONONUCLEAR; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; VACCINATION; VACCINES, SYNTHETIC; VIRAL LOAD; VIRAL MATRIX PROTEINS;

EID: 84894257959     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-11-21     Document Type: Article

References (46)

1. Historical perspective-emergence of influenza A (H1N1) viruses. Zimmer SM, Burke DS, N Engl J Med 2009 361 279 285 10.1056/NEJMra0904322 19564632
2. Influenza: vaccination and treatment. Stephenson I, Nicholson KG, Eur Respir J 2001 17 1282 1293 10.1183/09031936.01.00084301 11491177 (Pubitemid 32717491)
3. Seasonal inactivated influenza virus vaccines. Couch RB, Vaccine 2008 26S 5 9
4. Comparison of adverse reactions to whole-virion and split-virion influenza vaccines in hospital personnel. Al-Marou A, Scheifele DW, Soong T, Bjornson G, Can Med Assoc J 1991 145 213 218
5. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Song JM, Rooijen NV, Bozja J, Compans RW, Kang SM, PNAS 2011 108 757 761 10.1073/pnas.1012199108 21187388
6. Inactivated influenza virus vaccines in man: a comparative study of subunit and split vaccines using two methods for assessment of antibody responses. Jennings R, Smith TL, Spencer RC, Mellersh AM, Edey D, Fenton P, Potter CW, Vaccine 1984 2 75 80 10.1016/S0264-410X(98)90036-6 6531953 (Pubitemid 15167636)
7. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Beyer WEP, Palache AM, Jong JCD, Osterhaus ADME, Vaccine 2002 20 1340 1353 10.1016/S0264-410X(01)00471-6 11818152 (Pubitemid 34131675)
8. The annual production cycle for influenza vaccine. Gerdil C, Vaccine 2003 21 1776 1779 10.1016/S0264-410X(03)00071-9 12686093 (Pubitemid 36398372)
9. Mapping the antigenic and genetic evolution of influenza virus. Smith DJ, Lapedes AS, Jong JCD, Bestebroer TM, Rimmelzwaan GF, Osterhaus ADME, Fouchier RAM, Science 2004 305 371 376 10.1126/science.1097211 15218094 (Pubitemid 38938148)
10. Novel vaccines against influenza viruses. Kang SM, Song JM, Compans RW, Virus Res 2011 162 31 38 10.1016/j.virusres.2011.09.037 21968298
11. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Zhao G, Lin Y, Du I, Guan J, Sun S, Sui H, Kou Z, Chan CC, Guo Y, Jiang S, Zheng BJ, Zhou Y, Virol J 2010 7 2 8 10.1186/1743-422X-7-2 20051141
12. Plasmid DNA based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, Rolland A, Smith LR, J Infect Dis 2008 197 1643 1652 10.1086/588431 18513153 (Pubitemid 351919627)
13. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising are combinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Huleatt JW, Nakaara V, Desaia P, Huanga Y, Hewitt D, Jacobsa A, Tanga J, McDonalda W, Songb L, Evans RK, Umlaufb S, Tusseyb L, Powella TJ, Vaccine 2008 26 201 214 10.1016/j.vaccine.2007.10.062 18063235 (Pubitemid 50008089)
14. Characterization of immunity induced by M2e of influenza virus. Wu F, Huang JH, Yuan XY, Huang WS, Chen YH, Vaccine 2007 25 8868 8873 10.1016/j.vaccine.2007.09.056 18061317 (Pubitemid 350199590)
15. Protection against H1, H5, H6 and H9 influenza A infection with Liposomal matrix 2 epitope vaccines. Ernst WA, Kim HJ, Tumpey TM, Jansen AD, Tai W, Cramer DV, Adler-Moore JP, Fujii G, Vaccine 2006 24 5158 5168 10.1016/j.vaccine.2006.04.008 16713037 (Pubitemid 43818194)
16. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL, Emerg Infect Dis 2007 13 426 435 10.3201/eid1303.061125 17552096 (Pubitemid 46348126)
17. Vaxfectin formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, Lalor P, Leamy V, Vahle R, Luke CJ, Rolland A, Kaslow DC, Smith LR, Hum Vaccin 2007 3 157 164 10.4161/hv.3.5.4175 17637571 (Pubitemid 47598172)
18. Influenza virus-like particles containing M2 induce broadly cross protective immunity. Song JM, Wang BZ, Park KM, Rooijen NV, Quan FS, Kim MC, Jin HT, Pekosz A, Compans RW, Kang SM, PLoS One 2011 6 14538 10.1371/journal.pone. 0014538 21267073
19. Structure and mechanism of the M2 proton channel of influenza A virus. Schnell JR, Chou JJ, Nature 2008 451 591 595 10.1038/nature06531 18235503 (Pubitemid 351186272)
20. Research and development of universal influenza vaccines. Du L, Zhou Y, Jiang S, Microbes Infect 2010 12 280 286 10.1016/j.micinf.2010.01.001 20079871
21. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Liu W, Zou P, Chen YH, Immunol Lett 2004 93 131 136 10.1016/j.imlet.2004.03.003 15158608 (Pubitemid 38670365)
22. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. Zou P, Liu W, Chen YH, Int Immunopharmacol 2005 5 631 635 10.1016/j.intimp.2004.12.005 15710332 (Pubitemid 40248318)
23. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus. Moon HJ, Lee JS, Talactac MR, Chowdhury MYE, Kim JH, Park ME, Choi YK, Sung MH, Kim CJ, Vet Microbiol 2012 160 277 289 10.1016/j.vetmic.2012.05.035 22763171
24. Induction of the protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Zhao G, Du L, Xiao W, Sun S, Lin Y, Chen M, Kou Z, He Y, Lustigman S, Jiang S, Zheng BJ, Zhou Y, Vaccine 2010 28 7233 7240 10.1016/j.vaccine.2010.08.049 20732469
25. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ, Vaccine 1995 13 1399 1402 10.1016/0264-410X(95)92777-Y 8578816
26. In contrast to conventional inactivated influenza vaccines, 4×M2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Ebrahimi SM, Dabaghian M, Tebianian M, Jazi MHZ, Virology 2012 430 63 72 10.1016/j.virol.2012.04.015 22595444
27. Tandem repeats of the extracellular domain of Matrix 2 influenza protein exposed in Brucella lumazine synthase decameric carrier molecule induce protection in mice. Alvarez P, Zylberman V, Ghersi G, Boado L, Palacios C, Goldbaum F, Mattion N, Vaccine 2013 31 806 812 10.1016/j.vaccine.2012.11.072 23246552
28. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Kim MC, Song JM, Eunju O, Kwon YM, Lee YJ, Compans RW, Kang SM, Mol Ther 2013 21 485 492 10.1038/mt.2012.246 23247101
29. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. Jegerlehner A, Schmitz N, Storni T, Bachmann MF, J Immunol 2004 172 5598 5605 15100303 (Pubitemid 38542062)
30. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. Wu F, Yuan XY, Li J, Chen YH, Vaccine 2009 27 4320 4324 10.1016/j.vaccine.2009.04.075 19410621
31. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, et al. Nat Struct Mol Biol 2009 16 265 273 10.1038/nsmb.1566 19234466
32. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Vaccine 2009 27 6512 6521 10.1016/j.vaccine. 2009.08.053 19729082
33. Influenza. Cox NJ, Subbarao K, Lancet 1999 354 1277 1282 10.1016/S0140-6736(99)01241-6 10520648 (Pubitemid 29469365)
34. Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T, Subbu V, Spiro DJ, Sitz J, Koo H, Bolotov P, Dernovoy D, Tatusova T, Bao Y, George KS, Taylor J, Lipman DJ, Fraser CM, Taubenberger JK, Salzberg SL, Nature 2005 437 1162 1166 10.1038/nature04239 16208317 (Pubitemid 41509354)
35. Major issues and challenges of influenza pandemic preparedness in developing countries. Oshitani H, Kamigaki T, Suzuki A, Emerg Infect Dis 2008 14 875 880 10.3201/eid1406.070839 18507896 (Pubitemid 351838594)
36. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant. Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H, Chen Z, Arch Virol 2010 155 535 544 10.1007/s00705-010-0621-4 20195654
37. Antibody recognition of a highly conserved influenza virus epitop. Ekiert DC, Bhabha G, Elsliger MA, Friesen RHE, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA, Science 2009 324 246 251 10.1126/science.1171491 19251591
38. The highly conserved HA2 protein of the influenza a virus induces a cross protective immune response. Lee JS, Chowdhury MYE, Moon HJ, Choi YK, Talactac MR, Kim JH, Park ME, Son HY, Shin KH, Kim CJ, J Virol Methods 2013 194 280 288 10.1016/j.jviromet.2013.08.022 24004822
39. Modeling of protein refolding from inclusion bodies. Zhang T, Xu X, Shen L, Feng Y, Yang Z, Shen Y, Wang J, In W, Wang X, Acta Biochim Biophys Sin 2009 4 1044 1052
40. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. Shim BS, Choi YK CH, Yun Lee EG, Jeon YS, Park SM, Cheon IS, Joo DH, Cho CH, Song MS, et al. PLoS One 2011 6 27953 10.1371/journal.pone.0027953 22140491
41. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, Hamajima K, Yang J, Ishii N, Nakazawa M, Okuda K, Ohnari K, Nakajima K, Xin KQ, Vaccine 2001 19 3681 3691 10.1016/S0264-410X(01)00078-0 11395202 (Pubitemid 32522766)
42. DNA vaccine combining form of antigen and method of delivery to raise a spectrum of IFN-gamma and IL-4 producing CD4+ and CD8+ T cells. Oran AE, Robinson HL, J Immunol 2003 171 1999 2005 12902504 (Pubitemid 36974544)
43. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, Houser KV, Pearce MB, Pappas C, Tumpey TM, Epstein SL, PLoS One 2010 5 13162 10.1371/journal.pone. 0013162 20976273
44. Vaccination with hemagglutinin or neuraminidase DNA protects BALB/c mice against influenza virus infection in presence of maternal antibody. Chen J, Zhang F, Fang F, Chang H, Chen Z, BMC Infect Dis 2007 7 118 10.1186/1471-2334-7- 118 17939857
45. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin or neuraminidase-expressing DNA in BALB/c mice. Qiu M, Fang F, Chen Y, Wang H, Chen Q, Chang H, Wang F, et al. Biochem Biophys Res Commun 2006 343 1124 1131 10.1016/j.bbrc.2006.03.088 16580631
46. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Itoh Y, Shinya K, Kiso M, Nature 2009 460 1021 1027 19672242